ROS Therapeutics ApS: Financial statements 2022
CVR: 39507501
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
ROS Therapeutics ApS (CVR 39507501) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK -3,096,334 and a net result of DKK -3,350,372 compared with DKK -4,381,494 the year before. Equity in the 2022 report amounted to DKK -4,108,411. The company had 1 employee in the financial year.
- Gross Profit
- DKK -3,096,334
- Profit/Loss
- DKK -3,350,372
- Equity
- DKK -4,108,411
- Total Assets
- DKK 3,372,560
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | -3.1 mio. | -3.4 mio. | -4.1 mio. | 1 |
| 2021 | - | -4.8 mio. | -4.4 mio. | -758 t. | 1 |
| 2020 | - | -2 mio. | -1.9 mio. | 3.6 mio. | 1 |
| 2019 | - | -2.1 mio. | -1.9 mio. | 5 mio. | 0 |
Official annual report
Keep an eye on ROS Therapeutics ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
ROS Therapeutics ApS has published its annual report for 2021. Gross profit came to DKK -4,763,306, and the net result was DKK -4,381,494.
As of June 1, 2022, Henrik Castenholm Fenger has joined the board of directors of ROS Therapeutics ApS.
About ROS Therapeutics ApS
ROS Therapeutics ApS is a Danish company of the type Anpartsselskab based in Roskilde, founded in 2018. The company is in liquidation. The company is registered under the industry Fremstilling af farmaceutiske præparater. The management consists of Hanne Damgaard Jensen. The company is owned by Sandlykke A/S, HDJ & LEJ Invest ApS and ROS Therapeutics Holding ApS. The company has 1 employee (2022). In 2025, the company reported a gross profit of DKK -543,530 and a net result of DKK -1,212,924 compared with DKK -1,314,915 the year before. Equity in the 2025 report amounted to DKK -7,954,408.